Article
Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study.
Nature communications - 25 Mar 2026
Gounder Mrinal, Schöffski Patrick, Jones Robin L, Stacchiotti Silvia, Demetri George D, Cote Gregory M, Agulnik Mark, Chugh Rashmi, Jahan Thierry, Gupta Abha A, Chen Tom Wei-Wu, Ratan Ravin, Dileo Palma, Drilon Alexander, Malouf Gabriel G, Szanto Attila, Gupta Neal, Tannir Nizar M
Abstract excerpt
Advanced tumors harboring SWI/SNF mutations are rare and aggressive. Often presenting in young patients, treatment options are limited. This phase II basket study (NCT02601950) assessed oral tazemetostat, an EZH2 inhibitor, at 800 mg twice daily (N = 129). Cohorts included malignant rhabdoid tumors (n = 32, Cohort 1), synovial sarcoma (n = 33, Cohort 2), INI1-negative tumors (n = 32, Cohort 3), renal medullary...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.